BiotechTube

HRS-8427 + Imipenem and Cilastatin Sodium + HRS-8427 placebo + Imipenem and Cilastatin Sodium placebo

Phase 3Recruiting
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)

Conditions

Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)

Trial Timeline

Sep 25, 2024 → Nov 1, 2025

NCT ID
NCT06569056

About HRS-8427 + Imipenem and Cilastatin Sodium + HRS-8427 placebo + Imipenem and Cilastatin Sodium placebo

HRS-8427 + Imipenem and Cilastatin Sodium + HRS-8427 placebo + Imipenem and Cilastatin Sodium placebo is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06569056. Target conditions include Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP).

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06569056Phase 3Recruiting

Competing Products

20 competing products in Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)

See all competitors
ProductCompanyStageHype Score
ZY19489 + Ferroquine (FQ) + PlaceboZydus LifesciencesPhase 1
33
HRS -8427 + Imipenem and Cilastatin SodiumJiangsu Hengrui MedicinePhase 2
52
Ceftolozane/Tazobactam + Metronidazole + Meropenem + PlaceboMerckPhase 3
77
Vancomycin + Daptomycin + Semi-Synthetic PenicillinMerckApproved
85
CXA-201 and metronidazole + MeropenemMerckPhase 3
77
CXA-101 + CeftazidimeMerckPhase 2
52
Ceftolozane/Tazobactam + MeropenemMerckPhase 2
52
Imipenem+Cilastatin/RelebactamMerckPhase 3
77
Daptomycin + VancomycinMerckApproved
85
CXA-101/ tazobactam and metronidazole + meropenem plus saline placeboMerckPhase 2
52
CXA-201 + LevofloxacinMerckPhase 3
77
Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo for MetronidazoleMerckPhase 2
52
MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazoleMerckApproved
85
MK0826, /Duration of Treatment : 8 Weeks + Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 WeeksMerckPhase 3
77
KLU156 + CoartemNovartisPhase 3
77
LYS228 + Standard of care therapyNovartisPhase 2
52
Artemether-lumefantrine (COA566)NovartisPhase 2/3
65
INE963NovartisPhase 2
52
KAE609 + SoC (Coartem) + KLU156NovartisPhase 2
52
KAF156 + Coartem + Lumefantrine Solid Dispersion FormulationNovartisPhase 2
52

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85